Download PDF
Thromb Haemost 2021; 121(10): 1317-1325
DOI: 10.1055/a-1355-3716
Coagulation and Fibrinolysis

Transfusion with Cryoprecipitate for Very Low Fibrinogen Levels Does Not Affect Bleeding or Survival in Critically Ill Cirrhosis Patients

Isadore M. Budnick
1   Department of Medicine, University of Virginia, Charlottesville, Virginia, United States
,
Jessica P.E. Davis
2   Division of Gastroenterology and Hepatology, Center for the Study of Hemostasis in Liver Disease, University of Virginia, Charlottesville, Virginia, United States
,
Anirudh Sundararaghavan
1   Department of Medicine, University of Virginia, Charlottesville, Virginia, United States
,
Samuel B. Konkol
1   Department of Medicine, University of Virginia, Charlottesville, Virginia, United States
,
Chelsea E. Lau
1   Department of Medicine, University of Virginia, Charlottesville, Virginia, United States
,
James P. Alsobrooks
1   Department of Medicine, University of Virginia, Charlottesville, Virginia, United States
,
Matthew J. Stotts
2   Division of Gastroenterology and Hepatology, Center for the Study of Hemostasis in Liver Disease, University of Virginia, Charlottesville, Virginia, United States
,
Nicolas M. Intagliata
2   Division of Gastroenterology and Hepatology, Center for the Study of Hemostasis in Liver Disease, University of Virginia, Charlottesville, Virginia, United States
,
Ton Lisman
3   Section of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, Surgical Research Laboratory, University of Groningen, Groningen, The Netherlands
,
Patrick G. Northup
2   Division of Gastroenterology and Hepatology, Center for the Study of Hemostasis in Liver Disease, University of Virginia, Charlottesville, Virginia, United States
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Background Fibrinogen (FIB) levels less than 150 mg/dL have been associated with increased rates of bleeding and lower survival in critically ill cirrhosis patients.

Objective We aimed to determine if treatment with cryoprecipitate (CRYO) for low FIB levels is associated with bleeding outcomes or survival.

Methods A total of 237 cirrhosis patients admitted to an intensive care unit at a tertiary care liver transplant center with initial FIB levels less than 150 mg/dL were retrospectively assessed for CRYO transfusion, bleeding events, and survival outcomes.

Results The mean MELD score was 27.2 (95% confidence interval [CI]: 26.0–28.3) and CLIF-C acute on chronic liver failure score was 53.4 (51.9–54.8). Ninety-nine (41.8%) were admitted for acute bleeding and the remainder were admitted for nonbleeding illnesses. FIB level on admission correlated strongly with disease severity. After adjusting for disease severity, FIB on admission was not an independent predictor of 30-day survival (hazard ratio [HR]: 0.99, 95% CI: 0.99–1.01, p = 0.68). CRYO transfusion increased FIB levels but had no independent effect on mortality or bleeding complications (HR: 1.10, 95% CI: 0.72–1.70, p = 0.65).

Conclusion In cirrhosis patients with critical illness, low FIB levels on presentation reflect severity of illness but are not independently associated with 30-day mortality. Treatment of low FIB with CRYO also does not affect survival or bleeding complications, suggesting FIB is an additional marker of severity of illness but is not itself a direct factor in the pathophysiology of bleeding in critically ill cirrhosis patients.

Keywords

transfusion - portal hypertension - gastrointestinal bleeding - disseminated intravascular coagulation - international normalized ratio

Author Contributions

I.M.B.: aided in design and research plan and preformed data collection, manuscript writing, and editing; J.P.E.D., M.J.S., N.M.I.: aided in design, research plan, analysis, and editing manuscript; A.S., S.B.K., C.E.L., J.P.A.: data collection and validation; T.L.: aided in analysis and research design, critical review, and writing of manuscript; P.G.N.: conceptualization of project, study design, data collection/validation, analysis, writing of manuscript, and final editorial approval.




Publication History

Received: 15 October 2020

Accepted: 13 January 2021

Accepted Manuscript online:
15 January 2021

Article published online:
03 March 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Scaglione S, Kliethermes S, Cao G. et al. The epidemiology of cirrhosis in the United States: a population-based study. J Clin Gastroenterol 2015; 49 (08) 690-696
    CrossrefPubMedGoogle Scholar
  • 2 Allen AM, Kim WR, Moriarty JP, Shah ND, Larson JJ, Kamath PS. Time trends in the health care burden and mortality of acute on chronic liver failure in the United States. Hepatology 2016; 64 (06) 2165-2172
    Google Scholar
  • 3 McPhail MJW, Parrott F, Wendon JA, Harrison DA, Rowan KA, Bernal W. Incidence and outcomes for patients with cirrhosis admitted to the United Kingdom critical care units. Crit Care Med 2018; 46 (05) 705-712
    CrossrefPubMedGoogle Scholar
  • 4 Peery AF, Crockett SD, Murphy CC. et al. Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2018. W.B. Saunders; 2019: 254-272
    Google Scholar
  • 5 Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology 2017; 65 (01) 310-335
    Google Scholar
  • 6 Caldwell SH, Hoffman M, Lisman T. et al; Coagulation in Liver Disease Group. Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. Hepatology 2006; 44 (04) 1039-1046
    Google Scholar
  • 7 Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med 2011; 365 (02) 147-156
    CrossrefPubMedGoogle Scholar
  • 8 Northup PG, Caldwell SH. Coagulation in liver disease: a guide for the clinician. Clin Gastroenterol Hepatol 2013; 11 (09) 1064-1074
    CrossrefPubMedGoogle Scholar
  • 9 Stainsby D, MacLennan S, Thomas D, Isaac J, Hamilton PJ. British Committee for Standards in Haematology. Guidelines on the management of massive blood loss. Br J Haematol 2006; 135 (05) 634-641
    CrossrefPubMedGoogle Scholar
  • 10 Roberts LN, Patel RK, Arya R. Haemostasis and thrombosis in liver disease. Br J Haematol 2010; 148 (04) 507-521
    CrossrefPubMedGoogle Scholar
  • 11 Agarwal S, Joyner Jr KA, Swaim MW. Ascites fluid as a possible origin for hyperfibrinolysis in advanced liver disease. Am J Gastroenterol 2000; 95 (11) 3218-3224
    CrossrefPubMedGoogle Scholar
  • 12 Francis Jr RB, Feinstein DI. Clinical significance of accelerated fibrinolysis in liver disease. Haemostasis 1984; 14 (06) 460-465
    PubMedGoogle Scholar
  • 13 Violi F, Leo R, Basili S, Ferro D, Cordova C, Balsano F. CALC Group. Association between prolonged bleeding time and gastrointestinal hemorrhage in 102 patients with liver cirrhosis: results of a retrospective study. Haematologica 1994; 79 (01) 61-65
    PubMedGoogle Scholar
  • 14 Violl F, Basili S, Ferro D, Quintarelli C, Alessandril C, Cordova C. CALC Group. Association between high values of D-dimer and tissue-plasminogen activator activity and first gastrointestinal bleeding in cirrhotic patients. Thromb Haemost 1996; 76 (02) 177-183
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 De Pietri L, Bianchini M, Montalti R. et al. Thrombelastography-guided blood product use before invasive procedures in cirrhosis with severe coagulopathy: a randomized, controlled trial. Hepatology 2016; 63 (02) 566-573
    Google Scholar
  • 16 Lisman T, Leebeek FWG. Hemostatic alterations in liver disease: a review on pathophysiology, clinical consequences, and treatment. Dig Surg 24 (04) 250-258
    CrossrefPubMedGoogle Scholar
  • 17 Lisman T, Leebeek FWG, Mosnier LO. et al. Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology 2001; 121 (01) 131-139
    CrossrefPubMedGoogle Scholar
  • 18 Papatheodoridis GV, Patch D, Webster GJM, Brooker J, Barnes E, Burroughs AK. Infection and hemostasis in decompensated cirrhosis: a prospective study using thrombelastography. Hepatology 1999; 29 (04) 1085-1090
    CrossrefPubMedGoogle Scholar
  • 19 Intagliata NM, Argo CK, Stine JG, Lisman T, Caldwell SH, Violi F. Concepts and controversies in haemostasis and thrombosis associated with liver disease. Proceedings of the 7th International Coagulation in Liver Disease Conference. Georg Thieme Verlag; 2018: 1491-1506
    Google Scholar
  • 20 Drolz A, Horvatits T, Roedl K. et al. Coagulation parameters and major bleeding in critically ill patients with cirrhosis. Hepatology 2016; 64 (02) 556-568
    Google Scholar
  • 21 Giannini EG, Giambruno E, Brunacci M. et al. Low fibrinogen levels are associated with bleeding after varices ligation in thrombocytopenic cirrhotic patients. Ann Hepatol 2018; 17 (05) 830-835
    CrossrefPubMedGoogle Scholar
  • 22 Cho J, Choi SM, Yu SJ. et al. Bleeding complications in critically ill patients with liver cirrhosis. Korean J Intern Med (Korean Assoc Intern Med) 2016; 31 (02) 288-295
    CrossrefPubMedGoogle Scholar
  • 23 de Franchis R. Baveno VI Faculty. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol 2015; 63 (03) 743-752
    CrossrefPubMedGoogle Scholar
  • 24 Kaatz S, Ahmad D, Spyropoulos AC, Schulman S. Subcommittee on Control of Anticoagulation. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost 2015; 13 (11) 2119-2126
    CrossrefPubMedGoogle Scholar
  • 25 Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med 2015; 34 (28) 3661-3679
    CrossrefPubMedGoogle Scholar
  • 26 Stuart EA. Matching methods for causal inference: a review and a look forward. Stat Sci 2010; 25 (01) 1-21
    CrossrefPubMedGoogle Scholar
  • 27 Arroyo V, Moreau R, Kamath PS. et al. Acute-on-chronic liver failure in cirrhosis. Nat Rev Dis Primers 2016; 2: 16041
    Google Scholar
  • 28 Jalan R, Pavesi M, Saliba F. et al; CANONIC Study Investigators; EASL-CLIF Consortium. The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure. J Hepatol 2015; 62 (04) 831-840
    CrossrefPubMedGoogle Scholar
  • 29 Hugenholtz GC, Macrae F, Adelmeijer J. et al. Procoagulant changes in fibrin clot structure in patients with cirrhosis are associated with oxidative modifications of fibrinogen. J Thromb Haemost 2016; 14 (05) 1054-1066
    CrossrefPubMedGoogle Scholar
  • 30 Martinez J, Palascak JE, Kwasniak D. Abnormal sialic acid content of the dysfibrinogenemia associated with liver disease. J Clin Invest 1978; 61 (02) 535-538
    CrossrefPubMedGoogle Scholar
  • 31 Blasi A, Patel VC, Adelmeijer J. et al. Mixed fibrinolytic phenotypes in decompensated cirrhosis and acute-on-chronic liver failure with hypofibrinolysis in those with complications and poor survival. Hepatology 2020; 71 (04) 1381-1390
    Google Scholar
  • 32 Potze W, Adelmeijer J, Porte RJ, Lisman T. Preserved clot formation detected by the thrombodynamics analyzer in patients with cirrhosis. Thromb Res 2015; 135 (05) 1012-1016
    CrossrefPubMedGoogle Scholar
  • 33 Cholongitas E, Calvaruso V, Senzolo M. et al. RIFLE classification as predictive factor of mortality in patients with cirrhosis admitted to intensive care unit. J Gastroenterol Hepatol 2009; 24 (10) 1639-1647
    CrossrefPubMedGoogle Scholar